Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
109 studies found for:    Open Studies | "Hemophilia A"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Hemophilia A"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
Condition: Haemophilia A
Intervention: Biological: Optivate 500IU
2 Recruiting Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."
Condition: Hemophilia A
Intervention: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
3 Recruiting A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)
Condition: Hemophilia A
Intervention: Drug: Emicizumab
4 Recruiting Drug Use Investigation of Kovaltry in Hemophilia A Patients
Condition: Hemophilia A
Intervention: Drug: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)
5 Recruiting ADVATE Hemophilia A Outcome Database (AHEAD)
Condition: Hemophilia A
Intervention: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
6 Recruiting Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
Condition: Hemophilia A
Intervention: Drug: Plasma-derived FVIII/VWF concentrate
7 Recruiting An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: rFVIIIFc
8 Recruiting Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Condition: Severe Hemophilia A
Intervention: Drug: Alphanate SD/HT
9 Recruiting A Gene Transfer Study for Hemophilia A
Condition: Hemophilia A
Intervention: Genetic: SPK-8011
10 Recruiting Gene Therapy Study in Severe Haemophilia A Patients
Condition: Severe Haemophilia A
Intervention: Genetic: BMN 270
11 Not yet recruiting Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors
Condition: Hemophilia A With Inhibitor
Intervention:
12 Not yet recruiting Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
Condition: Hemophilia A
Intervention: Biological: BAY94-9027
13 Not yet recruiting Gene Therapy for Haemophilia A.
Condition: Hemophilia A
Intervention: Biological: AAV2/8-HLP-FVIII-V3
14 Recruiting National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A
Condition: Hemophilia A
Intervention: Behavioral: Educational Package
15 Not yet recruiting Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A
Condition: Hemophilia A
Interventions: Biological: SCT800;   Biological: Xyntha
16 Not yet recruiting Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A
Condition: Hemophilia A
Intervention: Biological: SCT800
17 Recruiting Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Condition: Hemophilia A
Intervention: Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
18 Recruiting Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia A
Condition: Hemophilia A
Interventions: Drug: Recombinant Factor VIII (50 IU/kg);   Drug: Recombinant Factor VIII (On-demand treatment)
19 Recruiting Phase 3b Continuation Study of the Safety and Efficacy of Prophylactic BAX 855 in PTPs With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: PEGylated Recombinant Factor VIII
20 Not yet recruiting A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A
Condition: Hemophilia A
Intervention: Drug: Emicizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.